Levodopa/Carbidopa Neuraxpharm

Levodopa, the active ingredient in Levodopa/Carbidopa Neuraxpharm, is a Levodopa/Carbidopa combination presented as an oral tablet for oral use. It is used to treat Parkinson's disease by restoring dopaminergic activity in patients with motor symptoms. GNH USA supplies Levodopa/Carbidopa Neuraxpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levodopa/Carbidopa acts on the dopaminergic pathway to improve motor function in Parkinsonian disorders. - Parkinson's disease: reduces rigidity, tremor and bradykinesia, improving daily activities. - Early‑stage Parkinsonism: enhances dopamine levels to delay progression of motor signs. - Advanced Parkinson's disease: provides more consistent symptom control when combined with other antiparkinson agents.

Levodopa/Carbidopa may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Orthostatic hypotension: dizziness upon standing. - Dyskinesia: involuntary movements, especially at higher doses. - Insomnia: difficulty falling or staying asleep. - Dry mouth: reduced salivation. - Constipation: slowed bowel movements.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: high fever, muscle rigidity, autonomic instability. - Severe psychiatric disturbances: hallucinations, delusions, depression. - Cardiac arrhythmias: irregular heart rhythm in susceptible patients. - Severe hypotension: marked drop in blood pressure leading to fainting.

Before initiating therapy, clinicians should evaluate patient history and monitor for potential complications. - Cardiovascular assessment: check for orthostatic hypotension and arrhythmias. - Psychiatric evaluation: monitor for hallucinations, depression or suicidal thoughts. - Renal/hepatic function: adjust dosing in severe impairment. - Concomitant MAO‑B inhibitors: avoid or separate dosing by at least 14 days. - Pregnancy and lactation: use only if benefits outweigh risks. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Levodopa/Carbidopa can interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Antipsychotics (e.g., haloperidol): may block dopamine receptors, reducing therapeutic effect. - High‑dose vitamin B6 (pyridoxine): increases peripheral decarboxylation, lowering central levodopa.

Moderate Interactions (Monitor Closely): - Iron supplements: decrease levodopa absorption; separate dosing by at least 2 hours. - Antihypertensives: additive effect on blood pressure, monitor for hypotension. - SSRIs/SNRIs: may increase risk of serotonin syndrome when combined with MAO‑B inhibitors.